About

Rubik Therapeutics' is a company with a singular focus on building smarter cancer therapies through data-driven biology and genomic precision.

We believe the best cancer drugs are borne from the tumor genome itself.
Our mission is to build safer, more effective treatments through selectivity.

Murray Robinson, PhD

Chief Executive Officer

Dr. Robinson is a biotechnology executive with a distinguished career discovering and developing cancer therapeutics. Dr. Robinson’s experience spans from gene discovery to approval, having developed small molecule, antibody, protein and cell therapy modalities in kidney, breast, lung and other tumor settings.

A scientist entrepreneur, Dr. Robinson first founded and built Amgen’s Cancer research effort (1991-2003) developing clinical stage programs comprising small molecule, antibody and protein therapeutic candidates. In 2003 Murray joined the executive team at start-up AVEO Pharmaceuticals (2003-2013), built the translational team and platform, playing key roles in business development and licensing, as well as working with the Clinical team to design and implement clinical studies for AVEO’s lead program Fotivda, a potent small molecule VEGFR inhibitor now approved for kidney cancer. In 2013 Murray leveraged his expertise in computational discovery to found Molquant, Inc., a translational genomics company with a unique computational platform to generate actionable insights from multi-omics data. In 2018, Dr. Robinson joined CAR-T startup Medisix as CSO, targeting blood cancers using technology from CAR pioneer Dario Campana. In 2021, Murray founded Rubik Therapeutics, combining computation and cell engineering to build a platform targeting solid tumors. Murray received his bachelor’s degree at the University of California at San Diego and his Ph.D. at the California Institute of Technology.

Andrew Astley, CFA

Chief Operating Officer

Mr. Astley's role as COO is to accelerate Rubik's growth through non dilutive business development and management of all non scientific aspects of the company. Mr. Astley is a seasoned business executive with more than 30 years experience in investment management industry. His leadership roles included Chief Operating Officer Europe, Africa and the Middle East, Global Head of Product and Marketing and Head of Sales for two of the largest and most innovative global investment management firms. Andrew received his bachelor's degree from University of Michigan and he is a Charter Financial Analyst (CFA).